Skip to content

Gross margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
70.5%0.0pp
Labcorp Holdings logo
Labcorp HoldingsLH
28.8%+0.9pp
Quest Diagnostics logo
Quest DiagnosticsDGX
33.2%+0.4pp
NeoGenomics logo
NeoGenomicsNEO
43.2%-1.1pp
GeneDx Holdings logo
GeneDx HoldingsWGS
69.6%+4.3pp
Personalis, Inc. logo
Personalis, Inc.PSNL
13.7%-19.6pp

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Calculated from Fulgent Genetics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s gross margin?
Fulgent Genetics, Inc. (FLGT) reported gross margin of 38.7% in Q1 2026.
How has Fulgent Genetics, Inc.'s gross margin changed year-over-year?
Fulgent Genetics, Inc.'s gross margin decreased by 0.2% year-over-year, from 38.8% to 38.7%.
What is the long-term trend for Fulgent Genetics, Inc.'s gross margin?
Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s gross margin has grown at a -12.4% compound annual growth rate (CAGR), from 78.7% to 40.6%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.